Peel Hunt reissued their buy rating on shares of Sinclair Pharma plc (LON:SPH) in a research note issued to investors on Tuesday, October 31st. The brokerage currently has a GBX 68 ($0.89) price target on the specialty pharmaceutical company’s stock.
Several other equities analysts have also recently weighed in on SPH. Jefferies Group LLC restated a buy rating and set a GBX 55 ($0.72) price target on shares of Sinclair Pharma plc in a report on Friday, September 29th. N+1 Singer restated a buy rating and set a GBX 37 ($0.49) price target on shares of Sinclair Pharma plc in a report on Tuesday, September 19th. Finally, Stifel Nicolaus restated a buy rating and set a GBX 71 ($0.93) price target on shares of Sinclair Pharma plc in a report on Tuesday, July 11th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Sinclair Pharma plc presently has a consensus rating of Buy and an average target price of GBX 53.20 ($0.70).
Sinclair Pharma plc (LON:SPH) traded down GBX 0.50 ($0.01) during trading hours on Tuesday, hitting GBX 28.63 ($0.38). The company had a trading volume of 70,972 shares, compared to its average volume of 204,131. Sinclair Pharma plc has a 12-month low of GBX 25.25 ($0.33) and a 12-month high of GBX 36.35 ($0.48).
Sinclair Pharma plc Company Profile
Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.
Receive News & Ratings for Sinclair Pharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma plc and related companies with our FREE daily email newsletter.